CLRB vs. NBRV, PDSB, ACRV, SKYE, TNYA, IMMX, OKUR, ANEB, AADI, and RPTX
Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Nabriva Therapeutics (NBRV), PDS Biotechnology (PDSB), Acrivon Therapeutics (ACRV), Skye Bioscience (SKYE), Tenaya Therapeutics (TNYA), Immix Biopharma (IMMX), OnKure Therapeutics (OKUR), Anebulo Pharmaceuticals (ANEB), Aadi Bioscience (AADI), and Repare Therapeutics (RPTX). These companies are all part of the "pharmaceutical products" industry.
Cellectar Biosciences vs.
Cellectar Biosciences (NASDAQ:CLRB) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation, dividends and community ranking.
Cellectar Biosciences has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Cellectar Biosciences' return on equity of 0.00% beat Nabriva Therapeutics' return on equity.
Cellectar Biosciences has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.
Cellectar Biosciences currently has a consensus price target of $12.50, indicating a potential upside of 4,313.84%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Nabriva Therapeutics.
Nabriva Therapeutics received 150 more outperform votes than Cellectar Biosciences when rated by MarketBeat users. Likewise, 54.74% of users gave Nabriva Therapeutics an outperform vote while only 54.00% of users gave Cellectar Biosciences an outperform vote.
16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 3.7% of Cellectar Biosciences shares are held by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Cellectar Biosciences has higher earnings, but lower revenue than Nabriva Therapeutics. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cellectar Biosciences had 2 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 3 mentions for Cellectar Biosciences and 1 mentions for Nabriva Therapeutics. Cellectar Biosciences' average media sentiment score of 0.72 beat Nabriva Therapeutics' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the media.
Summary
Cellectar Biosciences beats Nabriva Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Cellectar Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectar Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CLRB) was last updated on 4/16/2025 by MarketBeat.com Staff
Buy CLRB Stock Free CLRB Stock Alerts